The Centers for Medicare & Medicaid Services will not cover drugs when exclusively used for weight loss, like Ozempic or Wegovy, the Trump administration announced.

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

The proposal would have enabled more Americans to afford new medications in the GLP-1 class that have been shown to reduce weight.

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The Centers for Medicare and Medicaid (CMS) announced Friday it will not be finalizing a rule proposed by the Biden ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. Eli Lilly stock skidded.

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Shares of Eli Lilly, the seller of Zepbound, were down 2.7% to $718.50 after the close on Friday. Novo Nordisk, the maker of Wegovy, saw its stock decline 1.4% to $61.67. Shares of Hims & Hers, a ...

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

The Trump administration has decided not to back a Biden administration plan that would have allowed Medicare to pay for ...